Last updated: 11/07/2018 07:30:45
Effectiveness of belimumab treatment in a subpopulation of systemic lupus erythematosus (SLE) patients: a pooled analysis of BLISS-52 and BLISS-76
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Effectiveness of belimumab treatment in a subpopulation of systemic lupus erythematosus (SLE) patients: a pooled analysis of BLISS-52 and BLISS-76
Trial description: This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study. The primary objective is to evaluate the impact of belimumab treatment on a more severe subpopulation of systemic lupus erythematosus (SLE) subjects from BLISS-52 and BLISS-76 to aid physicians and payers in decision making. Subjects are from the modified Intent-to-Treat (ITT) population defined as randomized subjects who received at least 1 dose of study agent. This more severe subpopulation will have renal, neurological, haematological, or cardiovascular/respiratory organ domain involvement (as defined by a British Isles Lupus Assessment Group (BILAG) domain score of A, B or C in at least one of the domains) at baseline AND anti-double-stranded deoxyribonucleic acid (anti-dsDNA) positive (≥ 30 IU/mL) at baseline OR low C3 and/or C4 complement relative to the normal range at baseline.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Responder Rate
Timeframe: Week 52
Secondary outcomes:
SELENA SLEDAI
Timeframe: Week 52
SF-36
Timeframe: Week 24
Time to first flare by SLE Flare Index
Timeframe: Up to Week 52
Interventions:
Enrollment:
1016
Primary completion date:
Not applicable
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
Claude Schmitt, David A. Roth, Christi Kleoudis, Helen Birch . Efficacy of Belimumab in a Subpopulation of Systemic Lupus Erythematosus Patients With High Disease Activity in Key Organ Systems: Pooled BLISS Data. Lupus. 2013;22(1 suppl):1-96.
Medical condition
Systemic Lupus Erythematosus
Product
belimumab
Collaborators
Human Genome Sciences
Study date(s)
July 2009 to July 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Inclusion Criteria
- Eligible subjects for BLISS-52 and BLISS-76 included:
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion Criteria
- Eligible subjects for BLISS-52 and BLISS-76 included:
- clinical diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR) criteria
- “active” (systemic lupus erythematosus) SLE disease, defined as a safety of oestrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) disease activity score of at least 6 at screening
- an unequivocally positive antinuclear antibodies (ANA) test result, from 2 independent time points within the study screening period or 1 positive historical test result and 1 positive test result during the screening period. ANA test results obtained in the screening period were only considered positive if the ANA titer ≥ 1:80 and/or anti-dsDNA serum antibody was ≥ 30 IU/mL
- on a stable SLE treatment regimen for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (i.e., methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
- are anti-dsDNA positive (≥ 30 IU/mL) at baseline, OR
- have low C3 and/or C4 complement relative to the normal range at baseline. Exclusion Criteria:
- Key exclusion criteria for BLISS-52 and BLISS-76 included:
- severe active lupus nephritis or Central Nervous System (CNS) lupus
- pregnancy
- receipt of any B cell target therapy at any time
- receipt of an investigational agent within 60 days prior to Day 0 for non-biologics and within 1 year for biologics
- receipt of abatacept (within 1 year), intravenous (IV) cyclophosphamide (within 6 months), anti-tumor necrosis factor (anti-TNF) therapy, anakinra, IV immunoglobulin (IVIG), prednisone > 100 mg/day, or plasmapheresis within 3 months, or live vaccine within 1 month.
Additional inclusion criteria for the purpose of this analysis: subpopulation of patients from the pooled modified Intent-to-Treat population from BLISS-52 and BLISS-76 who have renal, neurological, haematological, or cardiovascular/respiratory organ domain involvement (as defined by a BILAG domain score of A, B or C in at least one of the domains) at baseline and 1 of the following:
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2010-19-07
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website